Company intelligence / Profile preview

P.G.F. Industry Solutions

Elixhausen, Salzburg, Austria

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

P.G.F. Industry Solutions developed and manufactured Granudacyn, a hypochlorous acid-based solution for wound cleansing and moistening that is commercially available and now part of Mölnlycke Health Care’s portfolio following the acquisition in October 2024[1].

Therapeutic areas: Dermatology
Modalities: DeviceBiologic (hypochlorous acid-based solutions)
Industry: Consumable Medical Devices

Drug pipeline

1 asset

Granudacyn

Commercial

Indications: Acute wounds, Chronic wounds, Burns

Partnerships

Mölnlycke Health Care (as acquirer/distribution partner)

Beyond the preview

Go deeper on P.G.F. Industry Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P.G.F. Industry Solutions.

Explore the full profile